Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Perretta

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Nefrologia|February 7, 2026
Urinary VEGF-A165b mRNA expression in Fabry disease: Pilot studySebastián Jaurretche, Germán Perez, Norberto Antongiovanni, et al.
Global Health, Epidemiology and Genomics|February 27, 2024
Baseline Characteristics of Fabry Disease "Amenable" Migalastat Patients in Argentinian CohortSebastián Jaurretche, Santiago Alonso, Mónica Calvo, et al.
Molecular Genetics and Metabolism Reports|April 25, 2025
Expert review in diagnostic, therapeutic and follow-up of Fabry disease in Latin America based on patient care standardsRoberto Giugliani, Juan Politei, Ana Martins, et al.
Pediatric Nephrology (Berlin, Germany)|July 11, 2018
Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?Juan Politei, Valeria Alberton, Oscar Amoreo, et al.
Molecular Genetics and Metabolism|March 14, 2025
Argentine program of home infusions with enzyme replacement therapy for lysosomal diseases: Results in safety, quality of life and adherenceGuillermo Drelichman, Juan M Politei, Nicolás Fernandez Escobar, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Nefrologia|February 7, 2026
Urinary VEGF-A165b mRNA expression in Fabry disease: Pilot studySebastián Jaurretche, Germán Perez, Norberto Antongiovanni, et al.
Global Health, Epidemiology and Genomics|February 27, 2024
Baseline Characteristics of Fabry Disease "Amenable" Migalastat Patients in Argentinian CohortSebastián Jaurretche, Santiago Alonso, Mónica Calvo, et al.
Molecular Genetics and Metabolism Reports|April 25, 2025
Expert review in diagnostic, therapeutic and follow-up of Fabry disease in Latin America based on patient care standardsRoberto Giugliani, Juan Politei, Ana Martins, et al.
Pediatric Nephrology (Berlin, Germany)|July 11, 2018
Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?Juan Politei, Valeria Alberton, Oscar Amoreo, et al.
Molecular Genetics and Metabolism|March 14, 2025
Argentine program of home infusions with enzyme replacement therapy for lysosomal diseases: Results in safety, quality of life and adherenceGuillermo Drelichman, Juan M Politei, Nicolás Fernandez Escobar, et al.
Pageof 2